BMO Capital Markets set a $51.00 price target on Bristol-Myers Squibb (NYSE:BMY) in a report published on Wednesday morning. The brokerage currently has a sell rating on the biopharmaceutical company’s stock.
Several other equities analysts have also recently weighed in on BMY. Citigroup raised their price target on shares of Bristol-Myers Squibb to $72.00 and gave the stock a buy rating in a research note on Wednesday, October 18th. Leerink Swann raised their price target on shares of Bristol-Myers Squibb from $61.00 to $72.00 and gave the stock an outperform rating in a research note on Monday, October 23rd. Piper Jaffray Companies reaffirmed a hold rating and set a $60.00 price target on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Credit Suisse Group reaffirmed a hold rating and set a $61.00 price target (up from $58.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Finally, SunTrust Banks raised shares of Bristol-Myers Squibb from a hold rating to a buy rating in a research note on Monday, October 30th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of Hold and a consensus price target of $66.73.
Bristol-Myers Squibb (BMY) opened at $68.96 on Wednesday. The firm has a market cap of $112,870.00, a P/E ratio of 29.22, a PEG ratio of 2.14 and a beta of 1.08. Bristol-Myers Squibb has a 52 week low of $51.56 and a 52 week high of $70.05. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.46 and a current ratio of 1.55.
The company also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Investors of record on Friday, January 5th were paid a $0.40 dividend. The ex-dividend date was Thursday, January 4th. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a dividend yield of 2.32%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 67.80%.
In related news, EVP Sandra Leung sold 156,582 shares of the firm’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the transaction, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Theodore R. Samuels II bought 4,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was purchased at an average cost of $62.30 per share, with a total value of $249,200.00. Following the completion of the purchase, the director now directly owns 22,000 shares of the company’s stock, valued at approximately $1,370,600. The disclosure for this purchase can be found here. 0.23% of the stock is currently owned by company insiders.
A number of institutional investors have recently made changes to their positions in BMY. Tradewinds Capital Management LLC lifted its holdings in Bristol-Myers Squibb by 34.6% during the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 500 shares during the last quarter. Delphi Private Advisors LLC acquired a new stake in Bristol-Myers Squibb during the 4th quarter valued at $108,000. Atlantic Trust LLC acquired a new stake in Bristol-Myers Squibb during the 2nd quarter valued at $111,000. Massey Quick Simon & CO. LLC lifted its holdings in Bristol-Myers Squibb by 523.5% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 1,492 shares during the last quarter. Finally, NuWave Investment Management LLC acquired a new stake in Bristol-Myers Squibb during the 4th quarter valued at $119,000. 69.56% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Bristol-Myers Squibb (BMY) Given a $51.00 Price Target by BMO Capital Markets Analysts” was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.chaffeybreeze.com/2018/02/18/bristol-myers-squibb-bmy-given-a-51-00-price-target-by-bmo-capital-markets-analysts.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.